Establishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong

AIDS Patient Care and STDs

Volumn 21, Issue 2, 2007, Pages 106-115

  Wong, Ka Hing ^a,b   Chan, Kenny Chi Wai ^a   Cheng, Kathy Lai Sim ^a   Chan, Wai Kit ^a   Kam, Kai Man ^b   Lee, Shui Shan ^c  

^a DEPARTMENT OF HEALTH   (Hong Kong)

^b DEPARTMENT OF HEALTH   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CHINESE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIAN CONTINENTAL ANCESTRY GROUP; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HONG KONG; HUMANS; MALE; MIDDLE AGED;

EID: 33847782188     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.0037     Document Type: Article

References (33)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26.
3. Wong KH, Chan KCW, Lee SS. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV disease during the era of highly active antiretroviral therapy. Clin Infect Dis 2004;39:853-860.
4. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
5. Kaplan JE, Hanson DL, Cohn DL, et al. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/μl. Clin Infect Dis 2003;37:951-958.
6. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001;15: 2251-2257.
7. Kam KM, Leung WL, Kwok MY, Hung MY, Lee SS, Mak WP. Lymphocyte subpopulation reference ranges for monitoring human immunodeficiency virus-infected Chinese adults. Clin Diagn Lab Immunol 1996;3:326-330.
8. Reichert T, DeBruyere M, Deneys V, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol 1991;60:190-208.
9. Wong KH, Lee SS, Kam KM. Decline of CD4 level and its correlation with clinical events in Chinese HIV-infected patients. J Infect Dis Antimicrob Agents 1998;15:99-103.
10. Hanson DL, Chu SY, Farizo KM, Ward JW. Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. The Adult and Adolescent Spectrum of HIV Disease Project Group. Arch Intern Med 1995;155: 1537-1542.
11. Scientific Committee on AIDS. Classification System for HIV Infection and Surveillance Case Definition for AIDS in Adolescents and Adults In Hong Kong. Hong Kong: Hong Kong Government Printer, 1995.
12. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1992;41:1-19.
13. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy. A collaborative analysis of prospective studies. Lancet 2002;360:119-129.
14. CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003;362:1267-1274.
15. Anastos K, Barron Y, Cohen MH, et al. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004; 140:256-264.
16. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-1430.
17. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001;358:1322-1327.
18. Phair JP, Mellors JW, Detels R, Margolick JB, Munoz A. Virologic and immunologic values allowing safe deferral of antiretroviral therapy. AIDS 2002;16: 2455-2459.
19. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003;138:620-626.
20. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286: 2568-2577.
21. Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, et al. When to start highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the ICONA study. AIDS 2001;15:983-990.
22. 9 cells/L. Ann Intern Med 2003;139:810-816.
23. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003;17:711-720.
24. Fong OW, Ho CF, Fung LY, et al. Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Med 2003;4:133-138.
25. Ho CF, Fong OW, Wong KH. Patient self-report as a marker of adherence to antiretroviral therapy. Clin Infect Dis 2002;34:1534-1535.
26. U.S. Public Health Service. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Updated October 29, 2004. www. aidsinfo.nih.org. (Last accessed February 20, 2005).
27. Kam KM, Wong KH, Li PC, Lee SS, Leung WL, Kwok MY. Proposed CD4(+) cell criteria for staging human immunodeficiency virus-infected Chinese adults. Clin Immunol Immunopathol 1998;89:11-22.
28. Lim WL, Xing H, Wong KH, et al. The lack of epidemiological link between the HIV type 1 infections in Hong Kong and Mainland China. AIDS Res Hum Retroviruses 2004;20:259-262.
29. Amornkul PN, Tansuphasawadikul S, Limpakarnjanarat K, et al. Clinical disease associated with HIV-1 subtype B′ and E infection among 2104 patients in Thailand. AIDS 1999;13:1963-1969.
30. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006;42:843-852.
31. Phillips AN, Lepri AC, Lampe F, Johnson M, Sabin CA. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 2003;17:1863-1869.
32. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004;38:1159-1166.
33. Joint United Nations Programme on HIV/AIDS. 2004 Report on the global AIDS epidemic, www.unaids. org (Last accessed December 25, 2005).